New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer

Tomas Kauer - Moderator

Sep 15, 2024 - 16:00

New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer

Tags:

Previous Article

Missile fired from Yemen set off sirens in central Israel, military says

Peace plan should not be imposed on Ukraine from the outside, US’s Sullivan says

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Tomas Kauer - Moderator

Related Posts

Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)

Gan & Lee Pharmaceuticals Presented Two Positive Clinic...

Tomas Kauer - Mode... Sep 14, 2024

Gladstone Investment Corporation Exits its Investment in Nth Degree, Inc.

Gladstone Investment Corporation Exits its Investment i...

Tomas Kauer - Mode... Sep 17, 2024

Median Technologies to Attend and Present at the ESMO Congress 2024, Being Held in Barcelona, Spain, from Sept 13-17, 2024

Median Technologies to Attend and Present at the ESMO C...

Tomas Kauer - Mode... Sep 12, 2024